The Latest Analyst Ratings For Geron
Portfolio Pulse from Benzinga Insights
In the last three months, Geron (NASDAQ:GERN) received diverse analyst ratings, with a shift towards more bullish perspectives in the recent 30 days. The average 12-month price target for GERN is now $4.75, up from $4.00, indicating an 18.75% increase. Analysts from Wedbush, Needham, and Goldman Sachs have maintained or raised their ratings and price targets, reflecting optimism about Geron's future performance. Geron, a clinical-stage biopharmaceutical company, is focused on developing cancer treatments but has seen a significant decline in revenue growth (-77.67%) and struggles with profitability and financial performance.
April 10, 2024 | 7:01 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Geron received increasingly bullish analyst ratings over the past three months, with a notable increase in the average price target to $4.75. Despite facing significant revenue decline and profitability challenges, the optimism from analysts could positively influence investor sentiment.
The shift towards more bullish analyst ratings and the increase in the average price target suggest a positive outlook for Geron's stock in the short term. Despite the company's financial challenges, such as a significant revenue decline and poor profitability metrics, the optimism from analysts, especially from reputable firms like Wedbush, Needham, and Goldman Sachs, could lead to increased investor confidence. This optimism is likely based on Geron's potential in developing cancer treatments, which may outweigh current financial difficulties in the eyes of investors.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100